Anna Maria Capelli,Fabrizio Micheli
Anna Maria Capelli
Agents interfering with the reuptake of catecholamines and tryptamines are well-known drugs capable of treating serious illnesses, including depression, pain and dependence. Further therapeutic applications and use have been tested and an i...
Anilkumar R Kore,Muthian Shanmugasundaram
Anilkumar R Kore
The pursuit of serine protease inhibitors as anticoagulants and anti-hepatitis C virus drugs continues to be an active area of research. Compounds such as P1-P3 macrocyclic peptides and linear peptides have been registered as potent hepatit...
Clearing the fog: patenting trends for the treatment of Alzheimer's disease [0.03%]
拨开迷雾：阿尔茨海默病治疗的专利趋势分析报告
Mike Lloyd,George Mokdsi,Doris Spielthenner
Mike Lloyd
This article asks, "What can Network Patent Analysis™ (NPA) tell us about developments in the treatment of this serious condition?" Patents filed for the treatment of Alzheimer's disease have been analyzed by NPA. NPA is an unique patent a...
Patent term extensions: issues, challenges and implications for pharmaceuticals [0.03%]
药品专利期限延长：问题、挑战及影响
Lisa Clark,Debbie Beadle
Lisa Clark
The standard term of a patent is 20 years from the date of filing. However, the time required for a pharmaceutical product to pass through research and development, and clinical trials to obtain regulatory approval can often be more than 10...
Obtaining, challenging and enforcing pharmaceutical patents under the America Invents Act [0.03%]
《美国发明法案》下的药品专利获取、挑战和保护制度
Lars H Genieser,Clifton E McCann
Lars H Genieser
The America Invents Act (AIA) will affect how intellectual property rights for pharmaceutical innovations are obtained, challenged and enforced. For example, the AIA allows pharmaceutical companies to take a more uniform approach in seeking...
Laurence Macphie,Noel Courage
Laurence Macphie
Stem cells are defined by their capability for both self-renewal through cell division and for producing a lineage capable of differentiating into one or more specialized cell types. Stem cells are found both in adult tissues and in the dev...
How do patent rights affect regulatory approvals and data exclusivity rights for pharmaceuticals in the EU? [0.03%]
欧盟的专利权如何影响药品的监管批准和数据独占权？
Peter Bogaert,Eveline Van Keymeulen
Peter Bogaert
This article sheds light on the relationship, or rather, absence of a relationship, between patent rights and regulatory approval procedures in the EU. The principle of 'patent linkage' has long been recognized and applied by regulatory aut...
'Reference composition' not 'lead compound': recent developments in case law for obviousness of pharmaceutical composition claims [0.03%]
“参考组合物”而非“先导化合物”——论药学领域组合物权利要求显而易见性判定中的案例法近发展动态
Steven L Highlander,Mark H Voges
Steven L Highlander
For most chemical compound claims, the obviousness analysis begins with the identification of a 'lead compound'. Pursuant to a recent decision from the Federal Circuit, a similar framework is now applicable for pharmaceutical composition cl...
Are natural products and medical diagnostic tests still eligible for patents in the USA? [0.03%]
在美国自然产物和医学诊断方法仍可申请专利吗？
Julian Cockbain,Sigrid Sterckx
Julian Cockbain
In 2010, the biotechnology and molecular diagnostics industries were shocked by the decision from a US District Court to the effect that isolated endogenous DNA and diagnostic tests based on newly discovered DNA sequences were not eligible ...
Lawrence S Perry,Jacqueline A Diramio
Lawrence S Perry